English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel released its final set of recommendations on February 29, 2024. This article includes a copy of the final guidelines and incorporates perspectives and lessons learned as the public health emergency ended.
Tag: SARS-Co-V2
UTHealth Houston researchers awarded $3.4M NIH grant to study pharmaceutical therapies to treat acute respiratory distress syndrome
A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.
An AI Tool That Can Help Forecast Viral Outbreaks
EVEscape predicts future viral mutations, new variants using evolutionary, biological information
Why Subvariants of the SARS-CoV-2 Virus Accelerated the Pandemic
UC San Diego researchers describe why SARS-CoV-2 subvariants spread more rapidly than the original virus strain, and how an early treatment might have made people more susceptible to future infections.
Personalized Exercise Program Improves Long COVID Symptoms
A supervised, eight-week exercise program improved symptoms of patients with long COVID better than the current standard self-managed rehabilitation recommendations. The study is published ahead of print in the Journal of Applied Physiology and was chosen as an APSselect article for February.
Experimental COVID-19 Vaccine Offers Long-term Protection Against Severe Disease
SARS-CoV-2 vaccines protected infant rhesus macaques against 1 severe lung disease after high dose challenge one year after vaccination.
Duke, UNC-Chapel Hill Scientists Identify New Antibody For COVID-19 and Variants
A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.